#United States #Los Angeles #Quintara Biosciences #Laragen Sanger Sequencing #Transnetyx

Quintara Biosciences Expands with Laragen Acquisition

Quintara Biosciences has officially completed the acquisition of Laragen's Sanger Sequencing business, previously operated by Transnetyx, as of September 15, 2025. This acquisition is a significant step for Quintara, allowing them to maintain uninterrupted service for current customers while further enhancing their strategic expansion in California's flourishing life sciences corridor.

Commitment to Continuity

Bob Bean, CEO of Transnetyx, expressed positive sentiments regarding the transition, noting that Quintara will continue providing exemplary service to Laragen's existing clientele in Los Angeles. This reassuring statement underscores the commitment to customer satisfaction, highlighting that all necessary services such as DNA sequencing, microbial identification, and cell line identification will remain intact. The integration ensures that the current operational team, state-of-the-art instruments, and customer-friendly drop-box network will continue to be available seamlessly.

Quintara's decision to honor existing pricing arrangements will further ease the transition process for customers, offering them peace of mind during this pivotal change.

Strategic Significance for the Industry

The Los Angeles area hosts renowned research institutions, including UCLA, Caltech, and City of Hope, marking it as a key location for biomedical research and innovation. By merging Laragen’s established market presence with Quintara's advanced sequencing capabilities, this acquisition not only enhances Quintara's service reach but also caters to the increasing demand for exceptionally high-quality life science services.

Daniel Wang, CEO of Quintara, articulated the firm’s dual commitment: "We aim to maintain continuity for researchers while expanding our strategic footprint." Strengthening their presence in Los Angeles links Quintara’s operations from the Bay Area to San Diego, allowing them to better serve the entire West Coast with improved turnaround times, expanded sequencing options, and enhanced operational resilience.

Operational Enhancements

Sue Zhao, General Manager of Quintara Biosciences, provided insights into the operational advantages of integrating Laragen’s services. "This acquisition not only boosts our throughput but strengthens our local sequencing infrastructure," she stated. The move not only supports the transition into long-read and high-throughput sequencing applications but also allows Quintara to offer comprehensive solutions that merge traditional Sanger sequencing workflows with cutting-edge sequencing platforms and molecular biology services.

About Quintara Biosciences

As a prominent Contract Research Organization/Contract Development and Manufacturing Organization (CRO/CDMO), Quintara specializes in a wide range of genomic and molecular biology services. With locations in Boston, San Francisco, San Diego, Los Angeles, and Houston, their offerings include Sanger sequencing, next-generation sequencing (NGS), Nanopore sequencing, molecular biology services, and solutions for recombinant antibody and protein production—designed to accelerate research and development efforts in the biotech and academic fields.

To learn more about their services, visit Quintara Biosciences.

About Transnetyx

Transnetyx is a global leader in automated genotyping solutions. The company has developed a diverse suite of products and services aimed at empowering researchers globally to achieve their discovery goals with efficiency. Operating out of Cordova, TN, with European outreach through their office in Darmstadt, Germany, Transnetyx emphasizes innovation and reliability in its global partnerships. For more information, visit Transnetyx.